- January 5, 2024– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple…
- January 5, 2024NEW YORK, January 5, 2024 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a biotechnology company developing a clinical…